Symphogen has built a dominant, long-term IP position within the field of antibody-based therapeutics. Issued and pending patents broadly cover Symphogen’s proprietary methods of discovering and manufacturing recombinant human polyclonal antibodies (rpAb) with its Symplex™ discovery technology and Sympress™ manufacturing platform. Symphogen also has issued and pending patents for the use of recombinant polyclonal antibodies for the prevention and treatment of allergy, treatment of Idiopathic Thrombocytopenic Purpura, and prophylaxis of Hemolytic Disease in Newborns.
Symphogen is unique in providing a viable industrial platform for producing rpAb, and its strong patent portfolio for rpAb discovery, manufacturing, characterization and application provides Symphogen with a fully-integrated platform to continually discover and develop new drugs that can fuel partnering opportunities and grow its proprietary pipeline.
Technology patents
Methods for cloning avian-derived antibodies Symphogen has patent applications pending on a further development of the Symplex™ technology aimed at isolation of variable region antibody sequences from chickens or other birds. This technology (chSymplex™) may e.g. be used to produce chimeric antibodies based on variable region sequences isolated from a transgenic chicken that expresses human immunoglobulin genes. The patent family includes WO 2010/022738 and equivalents. WO2010022738
Method for characterization of a recombinant polyclonal protein Symphogen has patent applications pending on a characterization platform for use to assess the amounts of different antibodies produced by a polyclonal cell line during production as well as batch-to-batch consistency of the antibodies present in the polyclonal products. The patent family includes WO 2009/065414.
Method for recombinant manufacturing of anti-RSV antibodies Symphogen has patent applications pending on the manufacture of recombinant anti-RSV antibodies, using production systems which are independent of site-specific integration. The patent family includes WO 2009/030237.
Recombinant polyclonal antibody production. Symphogen has patent applications pending on methods for manufacturing recombinant polyclonal antibody products based on random integration of the individual genes of interest into host cells. The patent family includes WO 2008/145133 and equivalents. WO2008145133
Cognate linkage of non-human variable heavy and light chains by Symplex™. Symphogen has patent applications pending on extension of the Symplex™ technology to allow isolation of murine variable antibody regions (mSymplex™). The mSymplex™ technique generates chimeric human/non-human antibodies. The patent family includes WO 2008/104184 and equivalents. WO2008104184
Characterisation of recombinant polyclonal antibody.
Symphogen has patent applications pending on methods for characterisation of a recombinant polyclonal antibody (rpAb). The patent includes methods for ensuring consistency and quality from batch to batch and verifying the presence and amount of the individual antibodies in the polyclonal antibody. The patent family includes WO 2006/007853 and equivalents, among these granted EP patent EP 1 787 126 B1. WO2006007853
Cognate linkage of variable heavy- and light chains – Symplex™ Symphogen has patent applications pending on the Symplex™ technology in PCT as well as in non-PCT member states. Symplex™ is a technique for high throughput isolation of original (i.e. cognate) pairs of antibody heavy and light chain variable region genes from human donor blood. The patent family includes WO 2005/042774 and equivalents, among these granted EP patent EP 1 670 912 B1.
Recombinant polyclonal antibody production – Sympress™ Symphogen has issued patents and patent applications pending on the Sympress™ technology, a manufacturing technology for the production of a recombinant polyclonal antibody (rpAb) in a single bioreactor. The rpAb constitutes a large diversity of individual antibody members produced in the same bioreactor, with a diversity which is maintained from batch to batch. The patent family includes WO 2004/061104 and equivalents, among these granted EP patent EP 1 583 830 B1.
Phage display – Symphage™ Symphogen has worldwide exclusive rights from Boston University to the Symphage™ technology, a technique for generating and screening libraries for recombinant polyclonal antibodies. The family includes WO 95/20401 and equivalents, among these issued US and EP patents: US 5,789,208; US 6,335,163; EP 1 231 268 B1; and EP 744 958 B1. WO9520401
Product patents
Pan-HER ligand traps.
Symphogen owns patent applications acquired from Receptor BioLogix on pan-HER ligand traps, which are engineered proteins combining an antibody-like element along with multiple HER (Human EGF Receptor) receptors designed to block ligands that stimulate tumor growth. These applications include WO 2007/146959
Treatment and prevention of severe respiratory disease.
Symphogen has another patent application pending on a recombinant polyclonal antibody for the treatment and prevention of RSV infections. The patent family includes WO 2008/106980 and equivalents. WO2008106980
Treatment of cancer.
Symphogen has patent applications pending on a recombinant polyclonal antibody (rpAb) for use in human cancer therapy. The rpAb binds to Epidermal Growth Factor Receptor (EGFR). The patent family includes WO 2008/104183 and equivalents.
Treatment and prevention of severe respiratory disease.
Symphogen has patent applications pending on a recombinant polyclonal antibody for the treatment and prevention of RSV infections. The patent family includes WO 2007/101441. WO2007101441
Treatment of ITP and prophylaxis of HDN
Symphogen has patent applications pending on an anti-Rhesus D recombinant polyclonal antibody (anti-RhD rpAb) suitable for prophylaxis of Hemolytic Disease of the Newborn (HDN) in Rhesus D-positive children of Rhesus D-negative women. Anti-RhD rpAb can also be used as treatment of Idiopathic Thrombocytopenic Purpura (ITP). The patent family includes WO 2006/007850 and equivalents.
Treatment of adverse effects of smallpox vaccination
Symphogen has patent applications pending on a recombinant polyclonal antibody for the treatment of adverse effects caused by smallpox vaccination and for the treatment and prophylaxis of orthopox infection in humans. The patent family includes WO 2007/065433. WO2007065433
Treatment or prevention of allergy
Symphogen has issued patents and pending patent applications on a recombinant polyclonal antibody for the treatment and prevention of allergy. The patent family includes WO 01/89563 and equivalents, among these issued patents US 6,849,259 and EP 1 283 720 B1. WO0189563
